Jade Biosciences (JBIO) Other Non-Current Liabilities (2021 - 2025)
Jade Biosciences' (JBIO) quarterly Other Non-Current Liabilities came in at $70000.0 in Q1 2025, little changed YoY from $70000.0 in Q1 2024, and down 99.93% on a QoQ basis from $107.6 million in Q4 2024.
Jade Biosciences (JBIO) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Jade Biosciences (JBIO) has 5 years of Other Non-Current Liabilities data on file, last reported at $70000.0 in Q1 2025.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $70000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $70000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $107.6 million, up 153614.29% from the prior year.
- Other Non-Current Liabilities declined to $70000.0 in Q1 2025, from $107.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $107.6 million in Q4 2024 to a low of $13000.0 in Q4 2021.
- A 5-year average of $7.7 million and a median of $70000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities declined 1.41% — and 2024, when it jumped 153614.29%.
- Tracing JBIO's Other Non-Current Liabilities over 5 years: stood at $13000.0 in 2021, then soared by 446.15% to $71000.0 in 2022, then retreated by 1.41% to $70000.0 in 2023, then jumped by 153614.29% to $107.6 million in 2024, then sank by 99.93% to $70000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $70000.0 (Q1 2025), $107.6 million (Q4 2024), and $70000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 70,000.00 |
| Dec 31, 2024 | 107.60 Mn |
| Sep 30, 2024 | 70,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 69,000.00 |
| Mar 31, 2023 | 70,000.00 |
| Dec 31, 2022 | 71,000.00 |
| Sep 30, 2022 | 13,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 13,000.00 |